Methods for the Estimation of the NICE Cost Effectiveness Threshold

Karl Claxton,^{1,2} Steve Martin,² Marta Soares,¹ Nigel Rice,^{1,2} Eldon Spackman,¹ Sebastian Hinde,¹ Nancy Devlin,³ Peter C Smith,⁴ Mark Sculpher¹

Centre for Health Economics, University of York, UK
 Department of Economics and Related Studies, University of York, UK
 Office of Health Economics, London, UK
 Imperial College, London, UK

What do we need?

- Compare
 - Health *expected* to be gained
 - Health *expected* to be lost due to additional NHS costs
- Expected health effects of changes in NHS expenditure
- What its not
 - Consumption value of health (willingness to pay)
 - Marginal productivity of 'ideal' NHS
- No simple relationship with changes in
 - Budget, prices and productivity
 - Health production outside NHS

How can we estimate it?

- Implied value from past decisions based on informal judgements
- Find out what decisions are made and estimate impact on cost and health
- Estimate the relationship between changes in expenditure and outcomes
 - 23 Programme Budget Categories (PBCs)
 - Disease areas (groups of ICD codes)
 - All expenditure allocated to each PBC
 - 152 Primary Care Trusts (PCTs)
 - Local areas of the NHS
 - Mortality within each PBC


NICE threshold Range 2004 (2001)


Appleby et al 2007

Martin et al 2008, 2009

How can we estimate effects of expenditure on mortality (deaths)?

- Change in PBC expenditure due to change in overall expenditure
 - Differences in spend on a particular PBC and total spend across PCTs
 - Account for other reasons why PBC spend might differ between PCTs
 - Isolate the effects on PBC spend of changes in overall expenditure
- Change in PBC mortality (deaths) due to change in PBC expenditure
 - Differences in PBC mortality and PBC expenditure across PCTs
 - Account for other reasons why PBC mortality might differ between PCTs
 - Isolate the effects on PBC mortality of changes in PBC expenditure






How can we estimate effects of expenditure on mortality?


Estimates of the threshold (2008-09)

	Cost per death averted
Qol associated with LYs	-
Qol during disease	-
YLL per death averted	-
QALYs per death averted	-
11 PBCs	
(with mortality)	£105,872
All 23 PBCs	£114,272


How can we estimate effects on life years



How can we estimate effects on life years



How can we estimate effects on life years




Estimates of the threshold (2008-09)


	Cost per death averted	Cost per life year
Qol associated with LYs	-	1
Qol during disease	-	0
YLL per death averted	-	4.5 YLL
QALYs per death averted	-	4.5 YLL
11 PBCs (with mortality)	£105,872	£23,360
All 23 PBCs	£114,272	£25,214

How can we adjust life years for quality?


- Life years lived at Qol norms by age and gender
 All disease is acute *or* symptoms are 'curable'
- Life years lived with Qol of disease (decrement to norms)
 - All disease is chronic (life long) and 'incurable'
- Assumptions are relaxed using measures of burden



How can we adjust life years for quality?




How can we adjust life years for quality?





Estimates of the threshold (2008-09)


	Cost per death averted	Cost per life year	Cost per QALY (mortality effects only)	
Qol associated with LYs	-	1	Norms	Disease
Qol during disease	-	0	0	0
YLL per death averted	-	4.5 YLL	4.5 YLL	4.5 YLL
QALYs per death averted	-	4.5 YLL	3.8 QALY	3.0 QALY
11PBCs (with mortality)	£105,872	£23,360	£28,045	£35,397
All 23 PBCs	£114, 272	£25,214	£30,270	£38,206

- No observations of quality life by PBC at PCT level
 - Quality of life is important in 11 PBCs with mortality
 - Mortality is (almost) irrelevant in the other 11 PBCs
 - Much NHS activity is primarily to improve quality of life
- Possible responses
 - Assume that NHS expenditure has no effects on quality of life
 - Surrogacy
 - Proportionate effect mortality burden used as surrogate for QoI effects
 - Extrapolation
 - Proportionate effect on QALY burden is similar in the other 11 PBCs
 - Use what can be observed to impute what cannot









Cost per QALY

(life year and

Estimates of the threshold (2008-09)

	Cost per death averted	Cost per life year	Cost per QALY (mortality effects)	Cost per QALY
Qol associated with LYs	-	1	Norms	Based on burden
Qol during disease	-	0	0	Based on burden
YLL per death averted	-	4.5 YLL	4.5 YLL	4.5 YLL
QALYs per death averted	-	4.5 YLL	3.8 QALY	12.7 QALY
11 PBCs (with mortality)	£105,872	£23,360	£28,045	£8,308
All 23 PBCs	£114,272	£25,214	£30,270	£12,936

What are the expected health consequences of £10m?

	Change in spend	Additional deaths	LY lost	Total QALY lost	Due to premature death	Quality of life effects
Totals	10 (£m)	51	233	773	150	623
Cancer	0.45	3.74	37.5	26.3	24.4	1.9
Circulatory	0.76	22.78	116.0	107.8	73.7	34.1
Respiratory	0.46	13.37	16.1	229.4	10.1	219.3
Gastro-intestinal	0.32	2.62	24.7	43.9	16.2	27.7
Infectious diseases	0.33	0.72	5.3	15.7	3.6	12.1
Endocrine	0.19	0.67	5.0	60.6	3.2	57.3
Neurological	0.60	1.21	6.5	109.1	4.3	104.8
Genito-urinary	0.46	2.25	3.3	10.6	2.1	8.5
Trauma & injuries*	0.77	0.00	0.0	0.0	0.0	0.0
Maternity & neonates*	0.68	0.01	0.4	0.2	0.2	0.1
Disorders of Blood	0.21	0.36	1.7	21.8	1.1	20.7
Mental Health	1.79	2.83	12.8	95.3	8.3	87.0
Learning Disability	0.10	0.04	0.2	0.7	0.1	0.6
Problems of Vision	0.19	0.05	0.2	4.2	0.2	4.1
Problems of Hearing	0.09	0.03	0.1	14.0	0.1	13.9
Dental problems	0.29	0.00	0.0	6.8	0.0	6.8
Skin	0.20	0.24	1.1	1.9	0.7	1.2
Musculo skeletal	0.36	0.39	1.8	23.2	1.2	22.1
Poisoning and AE	0.09	0.04	0.2	0.8	0.1	0.7
Healthy Individuals	0.35	0.03	0.2	0.7	0.1	0.6
Social Care Needs	0.30	0.00	0.0	0.0	0.0	0.0
Other (GMS)	1.01	0.00	0.0	0.0	0.0	0.0


Which PBCs matter most?

PBC	% spend	% health	Elasticity	PBC cost per QALY
Cancer	4.47	3.41	0.34	£16,997
Circulatory	7.59	13.95	1.40	£7,038
Respiratory	4.58	29.67	2.97	£1,998
Gastro-intestinal	3.20	5.68	0.57	£7,293
Infectious diseases	3.27	2.03	0.20	£20,829
Endocrine	1.89	7.84	0.78	£3,124
Neurological	5.98	14.11	1.41	£5,480
Genito-urinary	4.64	1.37	0.14	£43,813
Trauma & injuries*	7.70	0	0	NA
Maternity & neonates*	6.83	0.03	<0.01	£2,969,208
Disorders of Blood	2.06	2.82	0.28	£9,419
Mental Health	17.86	12.32	1.23	£18,744
Learning Disability	1.04	0.09	0.01	£149,883
Problems of Vision	1.94	0.55	0.05	£45,788
Problems of Hearing	0.87	1.81	0.18	£6,239
Dental problems	2.89	0.88	0.09	£42,472
Skin	1.97	0.25	0.03	£101,042
Musculo skeletal	3.63	3.00	0.30	£15,628
Poisoning and AE	0.93	0.11	0.01	£113,546
Healthy Individuals	3.53	0.09	0.01	£526,771
Social Care Needs	3.00	0	0	NA
Other	10.14	0	0	NA


How uncertain are the estimates?

An assessment of parameter uncertainty

Figure 5.1 Cumulative probability density function for the cost per QALY threshold



Implications of uncertainty in the estimate (Single threshold value that can be compared to an ICER)



k


Net Benefit

Is it likely to be an under or over estimate?


- Health effects over estimated (threshold underestimated)?
 - Deaths averted returns the individuals to the mortality risk of the general population (matched for age and gender)
 - Small positive correlation between expenditure and outcome elasticities
 - Apply estimates (data reported at PCT) to all PBC mortality
- Health effects under estimated (threshold overestimated)?
 - Mortality and quality of life effects restricted to one year
 - No effects of prevention (reduce incidence into the at risk population)
 - Effects of changes in GMS (and PBC22 & 16) expenditure not fully captured
- Other assumptions
 - Surrogacy
 - Are % mortality effects a good surrogate for % Qol effects?
 - Extrapolation
 - Is the proportionate effect on QALY burden of changes in spend similar in the other PBCs (e.g., Mental Health)?

Impact of investment and disinvestment?





How does the threshold change with overall



Summary of conclusions

- Upper bound of the NICE threshold is certainly too high
- Lower bound may also be too high
- Threshold less than the mean estimate when imposing costs on the NHS (reducing expenditure)
- No evidence of growth in threshold with increases in real budget and prices
- Some evidence that threshold more likely to fall rather than rise as NHS comes under more financial pressure
- Uncertainty in the estimate suggests a policy threshold set as less than the mean estimate
- Can reflect other displaced aspects of value

Accounting for other aspects of value?

- How much and what type of health and for whom?
 - Life years and quality of life effects
 - By age, gender and ICD code
- Severity, unmet need and burden
 - Burden of disease
 - Expected QALYs without and with disease
- Wider social benefits
 - Net production effects of a change in health
 - Marketed and non market production
 - Net of marketed and non marketed consumption

		Burden of Illness Absolute QALY loss	
Codo			Cod
Code	Disease (pharma ICDs). Cancer in blue.	↓	
C22	Liver cancer	10.70	
C25	Pancreatic cancer	9.97	MO
C34	Lung cancer	9.68	E1'
F20	Schizophrenia	7.62	M4
G35	Multiple sclerosis	6.18	F30
C92	Myeloid leukaemia	6.15	F20
G20	Parkinson's disease	4.60	J45 M8
C90	Myeloma	4.45	G3
J43	Emphysema and COPD	3.80	J43
<u>C64</u>	Kidney cancer	3.75	G4
F30	Depression	3.63	L4(
M05	Rheumatoid arthritis	2.83	dis
E11	Diabetes	2.68	E6
displ	(average displaced QALY)	2.07	C5
J45	Asthma	1.86	K50
G30	Alzheimer's disease	1.68	J3C
F03	Dementia	1.68	G2
G40	Epilepsy	1.32	C5
C18	Colon cancer	1.28	G3
126	Embolisms, fibrillation, thrombosis	1.16	zer
C61	Prostate cancer	1.06	A4
121	Acute myocardial infarction	1.00	F03
I 64	Stroke	0.83	164
C53	Cervical cancer	0.60	C1
C50	Breast cancer	0.55	C6
A40	Streptococcal septicaemia	0.38	<u>C6</u>
J30	Allergic rhinitis	0.30	121
M81	Osteoporosis	0.28	126
K50	Irritable Bowel Syndrome	0.26	J10
J10	Influenza	0.19	C9
L40	Psoriasis	0.19	C9
E66	Obesity	0.18	C2
 M45	Ankylosing spondylitis	0.11	C34 C25
	,		02

		Net production	
Code	Disease (pharma ICDs, n/a's	£	per QALY
	deleted). Cancer in blue.		
-		1	-
M05	Rheumatoid arthritis	£30,034	
E11	Diabetes	£27,421	
M45	Ankylosing spondylitis	£26,190	
F30	Depression	£23,489	
F20	Schizophrenia	£22,697	
J45	Asthma	£20,100	
M81	Osteoporosis	£17,910	
G35	Multiple sclerosis	£15,482	
J43	Emphysema and COPD	£14,525	
G40	Epilepsy	£14,245	
L40	Psoriasis	£11,890	
displ	(average displaced QALY)	£11,611	
E66	Obesity	£8,138	
C53	Cervical cancer	£6,912	
K50	Irritable Bowel Syndrome	£6,284	
J30	Allergic rhinitis	£5,234	
G20	Parkinson's disease	£3,102	
C50	Breast cancer	£2,888	
G30	Alzheimer's disease	£351	
zero	(zero Bol, WSB condition)	£0	
A40	Streptococcal septicaemia	-£513	
F03	Dementia	-£2,430	
I 64	Stroke	-£6,949	
C18	Colon cancer	-£8,061	
C61	Prostate cancer	-£10,602	
<u>C64</u>	Kidney cancer	-£13,211	
l21	Acute myocardial infarction	-£14,395	
126	Embolisms, fibrillation, thrombosis	-£16,752	
J10	Influenza	-£21,568	
C90	Myeloma	-£23,382	
C92	Myeloid leukaemia	-£24,813	
C22	Liver cancer	-£32,709	
C34	Lung cancer	-£36,067	
C25	Pancreatic cancer	-£53,860	

Attributes of investment and expected disinvestment

- Appraisal of ranibizumab (Lucentis) for diabetic macular oedema 2011
 - Retinal thickness \geq 400 subgroup before PAS
 - Additional costs = £3,506 per patient
 - Incremental cost-effectiveness = £25,000 (£13,322) per QALY
 - 23,000 eligible patients each year
- Attributes of benefit

Deaths LYs QALYs
0 0 3,225 (6,052)

• Approval will cost the NHS £80m p.a.

WSB of £26,432 (or 0.441 QALYs) per QALY gained (ICD E11)

per QALY displaced

• Attributes of benefit displaced each year


Deaths	LYs	QALYs
411	1,864	6,184

What type of data and research could improve the estimate?


- Longer and more complex lag structure
 - Duration of effect on mortality might be feasible (capture more health effects)
 - Estimating life year effect of mortality more problematic
- Simultaneous estimation across PBCs
 - Likely to capture more health effects
- Evolving PBC data (PCT and CCG boundaries)
- Extending measures of health outcome
 - Analysis of PROMs data
 - IAPT and mental health outcomes
- Incidence (age and gender) and duration of disease
 - WHO GBD
 - GPRD

Additional slides

• Reserve slides if needed during discussion




Estimating production and consumption effects Mechanism estimates prod / cons <u>without the treatment</u>..




International Classification of Disease (Chapter-level) Source: G Roberts, Department of Health

Estimating production and consumption effects ...which is compared to prod / cons <u>with treatment</u> to give impact



Estimating production and consumption effects

...which is compared to prod / cons with treatment to give impact



Raising this patient's QoL from 60% to 80% generates £200pcm in net prod / cons Source: G Roberts, Department of Health

Estimating production and consumption effects

Main data sources

Element	Dependent variables	Main data sources
Paid labour	AGQ	Annual Survey of Hours and Earnings (AG) Understanding Society (AQ)
Unpaid labour	AGQ	Time Use Survey (AG) Sick rate, derived from Understanding Soc. (Q)
Informal care	AGIQ	HoDAR
Formal care	A(I)Q	Adult Soc. Care Survey, GP Patient Survey, PSSRU data
Personal paid consumption	Α	Living Costs and Food Survey
Personal unpaid consumption	(const)	Time Use Survey
Government services	Α	Public Expenditure Statistical Analysis


A methodology for measuring the Production and Consumption effects of health treatments

1. Policy context


2. Defining the production and consumption effects of treatments

3. Estimating production and consumption effects






Results Net production (or consumption) as a function of age and QoL



NB this is the rate of net production in a given state – not the treatment impact

Production and consumption effects of health treatments Estimation for ICD populations with a reference dataset




Production and consumption effects of health treatments Estimates across select ICDs in reference dataset


ICD	Disease	£net prod	QALYs'	Net prod. vs
Cod	▼	per QALY	worth*	displaced
M05	Rheumatoid arthritis	30,034	0.50	
E11	Diabetes	27,421	0.46	
F30	Depression	23,489	0.39	
F20	Schizophrenia	22,697	0.38	
G43	Migraine	20,604	0.34	
J45	Asthma	20,100	0.33	
K02	Dental caries	20,004	0.33	
K25	Gastric ulcer	19,697	0.33	
M81	Osteoporosis	17,910	0.30	
G35	Multiple sclerosis	15,482	0.26	
G40	Epilepsy	14,245	0.24	
J03	Acute tonsillitis	13,011	0.22	
displ	(average displaced QALY)	11,611	0.19	
E66	Obesity	8,138	0.14	
C53	Cervical cancer	6,912	0.12	
G30	Alzheimer's disease	351	0.01	
l64	Stroke	-6,949	-0.12	
C18	Colon cancer	-8,061	-0.13	
C61	Prostate cancer	-10,602	-0.18	
l21	Acute myocardial infarction	-14,395	-0.24	
J10	Influenza	-21,568	-0.36	
C34	Lung cancer	-36,067	-0.60	
C25	Pancreatic cancer	-53,860	-0.90	

Production and consumption effects of health treatments

M05 Rheumatoid arthritis: results by category, and key inputs

Category	£ / QALY of gain
total production impact	24,529
Paid production	10,098
Unpaid production	14,431
total consumption impact	-5,505
Formal care consumption	-1,753
Informal care consumption	-8,012
Private paid consumption	1,490
Private unpaid consumption	1,653
Government consumption	1,116
TOTAL WSBs	30,034





		Burden of Illness Absolute QALY loss	
Cada			
	Disease (pharma ICDs). Cancer in blue.		
· ·		↓	_
C22	Liver cancer	10.70	
C25	Pancreatic cancer	9.97	
C34	Lung cancer	9.68	
F20	Schizophrenia	7.62	
G35	Multiple sclerosis	6.18	
C92	Myeloid leukaemia	6.15	
G20	Parkinson's disease	4.60	
C90	Myeloma	4.45	
J43	Emphysema and COPD	3.80	
<u>C64</u>	Kidney cancer	3.75	
F30	Depression	3.63	
M05	Rheumatoid arthritis	2.83	
E11	Diabetes	2.68	
displ	(average displaced QALY)	2.07	
J45	Asthma	1.86	
G30	Alzheimer's disease	1.68	
F03	Dementia	1.68	
G40	Epilepsy	1.32	
C18	Colon cancer	1.28	
l26	Embolisms, fibrillation, thrombosis	1.16	
C61	Prostate cancer	1.06	
l21	Acute myocardial infarction	1.00	
l64	Stroke	0.83	
C53	Cervical cancer	0.60	
C50	Breast cancer	0.55	
A40	Streptococcal septicaemia	0.38	
J30	Allergic rhinitis	0.30	
M81	Osteoporosis	0.28	
K50	Irritable Bowel Syndrome	0.26	
J10	Influenza	0.19	
L40	Psoriasis	0.19	
E66	Obesity	0.18	
M45	Ankylosing spondylitis	0.11	

		Burden of Illness - proportional (QALY loss / Expected QALYs if healthy)	
Code	Disease (pharma ICDs). Cancer in blue.	Expected QALYs if healthy	Prop shortfall
•			<u>_</u>
C22	Liver cancer	14	73%
C25	Pancreatic cancer	13	73%
C34	Lung cancer	14	71%
C92	Myeloid leukaemia	21	38%
G20	Parkinson's disease	17	31%
C90	Myeloma	19	31%
<u>C64</u>	Kidney cancer	28	
G35	Multiple sclerosis	46	
J43	Emphysema and COPD	26	17%
G30	Alzheimer's disease	11	14%
F03	Dementia	11	14%
F20	Schizophrenia	63	12%
M05	Rheumatoid arthritis	28	11%
C61	Prostate cancer	18	11%
126	Embolisms, fibrillation, thrombosis	22	11%
E11	Diabetes	27	11%
C18	Colon cancer	23	10%
l21	Acute myocardial infarction	19	9%
I 64	Stroke	24	8%
displ	(average displaced QALY)	42	8%
F30	Depression	58	6%
G40	Epilepsy	44	4%
J45	Asthma	61	4%
C5 0	Breast cancer	33	3%
C53	Cervical cancer	39	3%
L40	Psoriasis	13	
J10	Influenza	38	
M81	Osteoporosis	25	
J30	Allergic rhinitis	45	
A40	Streptococcal septicaemia	59	
K50	Irritable Bowel Syndrome	46	
E66	Obesity	66	0%
M45	Ankylosing spondylitis	30	0%
			Sourd

		Net production		
Code	Disease (pharma ICDs, n/a's	£ per QALY		
	deleted). Cancer in blue.			
		1	-	
M05	Rheumatoid arthritis	£30,034		
E11	Diabetes	£27,421		
M45	Ankylosing spondylitis	£26,190		
F30	Depression	£23,489		
F20	Schizophrenia	£22,697		
J45	Asthma	£20,100		
M81	Osteoporosis	£17,910		
G35	Multiple sclerosis	£15,482		
J43	Emphysema and COPD	£14,525		
G40	Epilepsy	£14,245		
L40	Psoriasis	£11,890		
displ	(average displaced QALY)	£11,611		
E66	Obesity	£8,138		
C53	Cervical cancer	£6,912		
K50	Irritable Bowel Syndrome	£6,284		
J30	Allergic rhinitis	£5,234		
G20	Parkinson's disease	£3,102		
C50	Breast cancer	£2,888		
G30	Alzheimer's disease	£351		
zero	(zero Bol, WSB condition)	£0		
A40	Streptococcal septicaemia	-£513		
F03	Dementia	-£2,430		
l64	Stroke	-£6,949		
C18	Colon cancer	-£8,061		
C61	Prostate cancer	-£10,602		
<u>C64</u>	Kidney cancer	-£13,211		
121	Acute myocardial infarction	-£14,395		
126	Embolisms, fibrillation, thrombosis	-£16,752		
J10	Influenza	-£21,568		
C90	Myeloma	-£23,382		
C92	Myeloid leukaemia	-£24,813		
C22	Liver cancer	-£32,709		
C34	Lung cancer	-£36,067		
C25	Pancreatic cancer	-£53,860		